155 related articles for article (PubMed ID: 8647853)
61. High-resolution structure of HLA-A*0201 in complex with a tumour-specific antigenic peptide encoded by the MAGE-A4 gene.
Hillig RC; Coulie PG; Stroobant V; Saenger W; Ziegler A; Hülsmeyer M
J Mol Biol; 2001 Jul; 310(5):1167-76. PubMed ID: 11502003
[TBL] [Abstract][Full Text] [Related]
62. A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein.
Zhang Y; Chaux P; Stroobant V; Eggermont AM; Corthals J; Maillère B; Thielemans K; Marchand M; Boon T; Van Der Bruggen P
J Immunol; 2003 Jul; 171(1):219-25. PubMed ID: 12817001
[TBL] [Abstract][Full Text] [Related]
63. Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay.
Scheibenbogen C; Lee KH; Stevanovic S; Witzens M; Willhauck M; Waldmann V; Naeher H; Rammensee HG; Keilholz U
Int J Cancer; 1997 Jun; 71(6):932-6. PubMed ID: 9185691
[TBL] [Abstract][Full Text] [Related]
64. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
[TBL] [Abstract][Full Text] [Related]
65. Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types.
Harada M; Li YF; El-Gamil M; Ohnmacht GA; Rosenberg SA; Robbins PF
J Immunother; 2001; 24(4):323-33. PubMed ID: 11565834
[TBL] [Abstract][Full Text] [Related]
66. Photoaffinity labeling of the T cell receptor on living cytotoxic T lymphocytes.
Romero P; Maryanski JL; Luescher IF
J Immunol; 1993 May; 150(9):3825-31. PubMed ID: 8473735
[TBL] [Abstract][Full Text] [Related]
67. ERAP2 Increases the Abundance of a Peptide Submotif Highly Selective for the Birdshot Uveitis-Associated HLA-A29.
Venema WJ; Hiddingh S; de Boer JH; Claas FHJ; Mulder A; den Hollander AI; Stratikos E; Sarkizova S; van der Veken LT; Janssen GMC; van Veelen PA; Kuiper JJW
Front Immunol; 2021; 12():634441. PubMed ID: 33717175
[TBL] [Abstract][Full Text] [Related]
68. HLA restriction and T-cell-receptor V beta gene expression of cytotoxic T lymphocytes reactive with human squamous-cell carcinoma of the head and neck.
Yasumura S; Weidmann E; Hirabayashi H; Johnson JT; Herberman RB; Whiteside TL
Int J Cancer; 1994 May; 57(3):297-305. PubMed ID: 8168988
[TBL] [Abstract][Full Text] [Related]
69. Hierarchy of Epstein-Barr virus-specific cytotoxic T-cell responses in individuals carrying different subtypes of an HLA allele: implications for epitope-based antiviral vaccines.
Khanna R; Burrows SR; Neisig A; Neefjes J; Moss DJ; Silins SL
J Virol; 1997 Oct; 71(10):7429-35. PubMed ID: 9311821
[TBL] [Abstract][Full Text] [Related]
70. Identification of cytotoxic T lymphocyte epitopes in dengue virus serotype 1.
Duan Z; Guo J; Huang X; Liu H; Chen X; Jiang M; Wen J
J Med Virol; 2015 Jul; 87(7):1077-89. PubMed ID: 25777343
[TBL] [Abstract][Full Text] [Related]
71. Amino acid identity and/or position determines the proteasomal cleavage of the HLA-A*0201-restricted peptide tumor antigen MAGE-3271-279.
Miconnet I; Servis C; Cerottini JC; Romero P; Lévy F
J Biol Chem; 2000 Sep; 275(35):26892-7. PubMed ID: 10859301
[TBL] [Abstract][Full Text] [Related]
72. Identification of two major HLA-B44 subtypes and a novel B44 sequence (B*4404). Oligotyping and solid phase sequencing of polymerase chain reaction products.
Yao Z; Keller E; Scholz S; McNicholas A; Volgger A; Albert ED
Hum Immunol; 1995 Jan; 42(1):54-60. PubMed ID: 7751160
[TBL] [Abstract][Full Text] [Related]
73. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine.
Hu X; Chakraborty NG; Sporn JR; Kurtzman SH; Ergin MT; Mukherji B
Cancer Res; 1996 Jun; 56(11):2479-83. PubMed ID: 8653680
[TBL] [Abstract][Full Text] [Related]
74. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
[TBL] [Abstract][Full Text] [Related]
75. DNA sequence of the coding region of the HLA-B44 gene.
Kottmann AH; Seemann GH; Guessow HD; Roos MH
Immunogenetics; 1986; 23(6):396-400. PubMed ID: 3459708
[TBL] [Abstract][Full Text] [Related]
76. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.
Benlalam H; Linard B; Guilloux Y; Moreau-Aubry A; Derré L; Diez E; Dreno B; Jotereau F; Labarrière N
J Immunol; 2003 Dec; 171(11):6283-9. PubMed ID: 14634146
[TBL] [Abstract][Full Text] [Related]
77. Identification of HLA-A2-restricted CTL epitope encoded by the MAGE-n gene of human hepatocellular carcinoma.
Dong HL; Li ZS; Ye J; Qu P; Huang YY; Wu W; Lu SY; Chen GS; Sui YF
Cancer Biol Ther; 2004 Sep; 3(9):891-8. PubMed ID: 15326372
[TBL] [Abstract][Full Text] [Related]
78. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.
Manici S; Sturniolo T; Imro MA; Hammer J; Sinigaglia F; Noppen C; Spagnoli G; Mazzi B; Bellone M; Dellabona P; Protti MP
J Exp Med; 1999 Mar; 189(5):871-6. PubMed ID: 10049951
[TBL] [Abstract][Full Text] [Related]
79. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
Shilyansky J; Nishimura MI; Yannelli JR; Kawakami Y; Jacknin LS; Charmley P; Rosenberg SA
Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2829-33. PubMed ID: 7511820
[TBL] [Abstract][Full Text] [Related]
80. A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes.
Fujie T; Tahara K; Tanaka F; Mori M; Takesako K; Akiyoshi T
Int J Cancer; 1999 Jan; 80(2):169-72. PubMed ID: 9935194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
